Tetsuya Akaishi1, Ichiro Nakashima2, Takayuki Takeshita3, Shunji Mugikura4, Douglas Kazutoshi Sato5, Toshiyuki Takahashi6, Shuhei Nishiyama7, Kazuhiro Kurosawa8, Tatsuro Misu9, Toru Nakazawa10, Masashi Aoki11, Kazuo Fujihara12. 1. Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: t-akaishi@med.tohoku.ac.jp. 2. Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: nakashima@med.tohoku.ac.jp. 3. Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: takeshita.oph@me.com. 4. Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: mugi844@gmail.com. 5. Department of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: douglas.sato@med.tohoku.ac.jp. 6. Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Neurology, Yonezawa National Hospital, Yonezawa, Japan. Electronic address: t-toshiyuki@mta.biglobe.ne.jp. 7. Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: snishym@med.tohoku.ac.jp. 8. Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: kaizaahige@gmail.com. 9. Department of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: misu@med.tohoku.ac.jp. 10. Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: ntoru@oph.med.tohoku.ac.jp. 11. Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: aokim@med.tohoku.ac.jp. 12. Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: fujikazu@med.tohoku.ac.jp.
Abstract
OBJECTIVES: The visual acuity prognoses of patients with neuromyelitis optica (NMO) are worse than those with optic neuritis (ON) caused by other diseases. Predicting the prognoses of ON at the time of onset is important for selecting treatments for NMO patients. METHODS: Twenty-three consecutive anti-aquaporin-4 autoantibody-positive NMO patients who presented with ON and had contrast-enhanced optic MRIs in the acute phase of their first ON episode were examined. Optical coherence tomographies (OCTs) were also examined for 22 of them. The visual acuity at the final follow-up, as assessed with the logMAR scale more than three years after ON onset, served as the outcome measure. These variables were also collected from 12 patients with serum anti-myelin oligodendrocyte glycoprotein antibody (anti-MOG-Ab). RESULTS: The strongest predictor of visual prognosis was the axial ON lesion length in the acute phase (R=0.747, p<0.0001), which was not observed in patients with anti-MOG-Ab. Specifically, the ON lesion length within the intra-orbit and canalicular segments exhibited the strongest correlation with visual prognosis (R=0.783, p<0.0001). The ON onset age was also correlated with visual prognosis (R=0.435, p=0.0338). OCT data in the chronic phase also showed a correlation with visual prognosis, but they were much weaker than the ON lesion length in the acute phase. CONCLUSIONS: The ON lesion length in the acute phase was an important predictor of the visual prognoses of NMO patients.
OBJECTIVES: The visual acuity prognoses of patients with neuromyelitis optica (NMO) are worse than those with optic neuritis (ON) caused by other diseases. Predicting the prognoses of ON at the time of onset is important for selecting treatments for NMO patients. METHODS: Twenty-three consecutive anti-aquaporin-4 autoantibody-positive NMO patients who presented with ON and had contrast-enhanced optic MRIs in the acute phase of their first ON episode were examined. Optical coherence tomographies (OCTs) were also examined for 22 of them. The visual acuity at the final follow-up, as assessed with the logMAR scale more than three years after ON onset, served as the outcome measure. These variables were also collected from 12 patients with serum anti-myelin oligodendrocyte glycoprotein antibody (anti-MOG-Ab). RESULTS: The strongest predictor of visual prognosis was the axial ON lesion length in the acute phase (R=0.747, p<0.0001), which was not observed in patients with anti-MOG-Ab. Specifically, the ON lesion length within the intra-orbit and canalicular segments exhibited the strongest correlation with visual prognosis (R=0.783, p<0.0001). The ON onset age was also correlated with visual prognosis (R=0.435, p=0.0338). OCT data in the chronic phase also showed a correlation with visual prognosis, but they were much weaker than the ON lesion length in the acute phase. CONCLUSIONS: The ON lesion length in the acute phase was an important predictor of the visual prognoses of NMO patients.
Authors: S Jarius; F Paul; O Aktas; N Asgari; R C Dale; J de Seze; D Franciotta; K Fujihara; A Jacob; H J Kim; I Kleiter; T Kümpfel; M Levy; J Palace; K Ruprecht; A Saiz; C Trebst; B G Weinshenker; B Wildemann Journal: Nervenarzt Date: 2018-12 Impact factor: 1.214
Authors: Joachim Havla; T Kümpfel; R Schinner; M Spadaro; E Schuh; E Meinl; R Hohlfeld; O Outteryck Journal: J Neurol Date: 2016-11-14 Impact factor: 4.849
Authors: Joachim Havla; Thivya Pakeerathan; Kevin Rostasy; Ilya Ayzenberg; Carolin Schwake; Jeffrey L Bennett; Ingo Kleiter; Ana Felipe-Rucián; Stephanie C Joachim; Amelie S Lotz-Havla; Tania Kümpfel; Markus Krumbholz; Eva M Wendel; Markus Reindl; Charlotte Thiels; Thomas Lücke; Kerstin Hellwig; Ralf Gold Journal: J Neuroinflammation Date: 2021-05-29 Impact factor: 8.322